Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amedisys

97.89
+0.38000.39%
Post-market: 97.890.00000.00%16:33 EDT
Volume:410.52K
Turnover:40.13M
Market Cap:3.21B
PE:36.05
High:97.95
Open:97.36
Low:97.36
Close:97.51
Loading ...

Amedisys Price Target Maintained With a $101.00/Share by Stephens & Co.

Dow Jones
·
04 Mar

Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)

TIPRANKS
·
03 Mar

AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises

Zacks
·
03 Mar

William Blair Reaffirms Their Hold Rating on Amedisys (AMED)

TIPRANKS
·
27 Feb

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Amedisys (AMED) and CSPC Pharmaceutical Group (OtherCHJTF)

TIPRANKS
·
27 Feb

Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks
·
27 Feb

Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates

Zacks
·
27 Feb

Amedisys Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Amedisys Reports Q4 2024 Financial Results Amid Merger Plans

TIPRANKS
·
27 Feb

Amedisys Q4 2024 Adj. EPS $0.96 Misses $1.05 Estimate, Sales $598.052M Miss $598.576M Estimate

Benzinga
·
27 Feb

Amedisys: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

BRIEF-Amedisys Q4 Net Income USD -20.4 Million

Reuters
·
27 Feb

Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

GlobeNewswire
·
27 Feb

UnitedHealth Refutes WSJ Report on New DOJ Probe; Stock Tumbles Intraday

MT Newswires
·
22 Feb

UnitedHealth Stock Falls on Report DOJ Is Probing Its Medicare Billing Practices -- Barrons.com

Dow Jones
·
21 Feb

UnitedHealth now has to fight the government on another front. The stock is sinking.

Dow Jones
·
21 Feb

UnitedHealth Under DoJ Investigation Over Medicare Billing Practices

GuruFocus.com
·
21 Feb

UnitedHealth sinks on WSJ report of DoJ launching probe into Medicare practices

Investing.com
·
21 Feb

Amedisys Price Target Maintained With a $101.00/Share by Stephens & Co.

Dow Jones
·
12 Feb

Amedisys (AMED) Earnings Expected to Grow: Should You Buy?

Zacks
·
12 Feb